The global onychomycosis treatment market is expected to hold a value worth US$ 4,738.3 million in 2023. From 2023 to 2033, the onychomycosis treatment market is likely to exhibit a CAGR of 8.4% while garnering a value worth US$ 10,608.8 million. The market's growth can be attributed to the growing prevalence of diabetes, which results in high risks of nail fungus infection.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value (2023) | US$ 4,738.3 million |
| Anticipated Forecast Value (2033) | US$ 10,608.8 million |
| Projected Growth Rate (2023 to 2033) | 8.4% |
Onychomycosis is a fungal infection that occurs in the fingernails and toenails that can result in chronic pain, disfigurement, and discomfort. The disease is characterized by symptoms such as whitish to yellow-brown discoloration, distortion in the shape of nails, and ragged and crumbly texture of the nails.
It is generally diagnosed through potassium, oxygen, and hydrogen examination, culture, and histopathological examinations of nail clippings and nail biopsies and is treated with laser therapy and photodynamic therapies.
The growing prevalence of chronic illnesses like human immunodeficiency virus (HIV), diabetes and peripheral artery disease (PAD), and onychomycosis is one of the key factors driving the market growth during the forecast period. Also, the expanding geriatric population, prone to such disorders due to the weakened immune system, is likely to fuel the demand for treatment during the forecast period.
Besides, the condition is highly prevalent among millennials and adults owing to the rising exposure to public swimming pools and the usage of tight clothes, shoes, and socks. Other factors adding to the market growth include topical nail lacquers and ointments to maintain nail hygiene, along with the significant developments in the healthcare infrastructure as likely to augment the market size in the forthcoming time.
Additionally, increasing approvals for novel products in the industry are expected to grow the market in the assessment period. For instance, in 2022, Zydus Lifesciences received approval from the US health regulator to market an antifungal Efinaconazole Topical Solution. The company received the final approval from the United States FDA to market the product. Such factors are likely to widen the market growth scope during the forecast period.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The expansion of the market can be attributed to increasing awareness about the threats of onychomycosis and increasing adoption of drug therapies, which are likely to have contributed significantly to the development of the market.
Further, increasing cases of age-related onychomycosis is another cause that is expected to have benefitted the market. Also, increasing approval by the regulatory authorities is another vital factor that has contributed to the market growth. For instance, in July 2021, Lupin received approval to launch Tavaborole Topical Solution, 5 % in the United States from the United States FDA.
Tavaborole Topical Solution is a generic equivalent of Kerydin Topical Solution, 5%, of Anacor Pharmaceuticals, and is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails owing to Trichophyton rubrum or Trichophyton mentagrophytes.
From 2023 to 2033, the global onychomycosis treatment market is anticipated to display a CAGR of 8.4%. The expansion of the market during the aforementioned period can be attributed to the increasing prevalence of diabetes across the globe. Diabetic patients are susceptible to toenail fungus.
Various studies and research have been performed to understand whether diabetic people experience a greater risk of onychomycosis than those without diabetes; most studies concluded that they do. Such factors are expected to benefit the market during the forecast period.
Increasing Shift toward Topical Solutions to Benefit the Market
As per the analysis, the increasing preference for topical treatment solutions is expected to play a significant role in developing the market during the forecast period. Per a survey conducted on dermatologists and podiatrists in the United States, 7 out of 10 doctors avoid prescribing oral terbinafine due to the risk of liver damage.
Another factor contributing to the market growth is the increasing prevalence of toenail infection caused due to onychomycosis. As per a study, about 10% of the world’s general population suffers from onychomycosis, with 35 to 40 million Americans being infected with nail fungus. This is anticipated to favor market growth in the coming time.
Also, the growing approval of medications by the regulatory authorities is anticipated to augment the market size significantly during the forecast period.
For instance, in 2020, Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, obtained FDA approval for a supplemental New Drug Application (sNDA) for Jublia (efinaconazole) topical solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails. Such factors are expected to benefit the market during the forecast period.
Principal Consultant
Lack of Awareness to Hinder the Market
The most significant factor affecting the market negatively includes the lack of awareness regarding the condition. People tend to ignore the symptoms of onychomycosis, such as decolorization, thickening of the nails, and separation of nails from the nail bed.
Because of this, the nail fungal infection remains undiagnosed. Further, people refrain from the treatment as they are not aware of the prevailing condition. Thus, the market is likely to suffer in the coming time. Another factor hampering the market is the side effects of the onychomycosis treatment drugs. Thus, the market is projected to suffer in the assessment period.
Increasing Research and Development Investment by Pharmaceutical Companies to Offer Remunerative Opportunities
The disease's growing prevalence has resulted in a significant investment in research and development by pharmaceutical companies for the development of novel therapeutics. Various available topical treatment solutions fail to penetrate deep inside the nail bed and, thus, do not cure the infection completely. Various players are investing significantly to offer novel drugs to meet the growing demand to cure the condition.
For instance, Hexima is conducting a phase I/IIa clinical study on HXP124, a plant defensin anti-fungal molecule for dermatophytes onychomycosis treatment. HXP124 witnessed a greater penetration rate as compared to Jublia and Kerydin. Such factors are anticipated to offer remunerative opportunities for expansion in the forthcoming time.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Availability of Medicines in Hospitals to Benefit the Segmental Growth in the Forecast Period
According to the analysis, the hospital segment is anticipated to be valued at more than US$ 2.2 Billion in 2022. The development of the segment can be attributed to the availability of medicines and other medical facilities there.
Also, an increase in privately owned clinics and the rise in dermatologists and podiatrists are likely to develop the segment in the forecast period.
Increasing Research and Development on Drugs to Favor Segmental Growth
| Segment | Drugs |
|---|---|
| Market Share % (2022) | 59.4% |
According to the analysis, the drug segment is expected to claim more than 59.4% of the global revenue during the forecast period. The domination of the segment can be attributed to the increasing focus on research and development and the convenience of this treatment type. Thus, the segment is likely to witness notable growth during the forecast period.
| Region | North America |
|---|---|
| Market Share % (2022) | 33.6% |
According to the analysis, the onychomycosis treatment market in North America is expected to dominate the global market during the forecast period. The region is projected to account for a more than 33.6% market share in 2023.
The United States is anticipated to significantly contribute to developing the industry in the assessment period. The domination of the regional market can be attributed to the increasing initiatives of players to study the disease.
For instance, in October 2020, Pfizer Inc. announced that it had commenced clinical studies on onychomycosis. The first phase involved research on whether the AN2690 topical solution is effective for onychomycosis of the toenail.
The second stage involved an open-label study to understand the safety and pharmacokinetics of the tavaborole 5% topical solution to treat distal subungual onychomycosis of the toenail in children and adolescents.
Another factor contributing to the market growth is the increasing cases of diabetes. As per CDC, 37.3 million Americans, or 1 in 10, have diabetes. Such stats are expected to benefit the market in the forecast period.
| Region | Europe |
|---|---|
| Market Share % (2022) | 28.8% |
As per the study, the European onychomycosis treatment market is anticipated to display a market share of more than 28.8% in 2023. The United Kingdom is projected to make a significant contribution to developing the regional market during the forecast period. The development of the regional market can be attributed to the growing initiatives by the government to spread awareness among citizens.
For instance, the British Association of Dermatologists offers patient information leaflets for fungal infections of the nails. Such factors are expected to benefit the onychomycosis treatment market in Europe during the forecast period.
| Countries | Market Share % (2022) |
|---|---|
| China | 13.2% |
| India | 10.8% |
According to the study, the Asia Pacific is projected to exhibit maximum market growth during the forecast period. The rapid development of the regional market can be attributed to various developing countries making significant contributions to advancing healthcare services.
For instance, in 2020, Kaken Pharmaceuticals Co., Ltd. announced the launch of Jublia in Hong Kong for dermatophytic onychomycosis treatment. Such initiatives are expected to drive the market in the Asia Pacific during the forecast period.
Blueberry Therapeutics, Richpoint Pharma (Canada), ToeFX (Canada), and Hallux (US) are emerging names in the global onychomycosis treatment industry.
Recent Development in the Startup Landscape
In December 2020, Hallux, a United States-based player, completed a US$ 7.1 million Series A expected to allow it to conduct Phase IIa clinical trials of its drug/device combination product for onychomycosis.
Key players in the global onychomycosis treatment market include Teva Pharmaceutical Industries Ltd., Sanofi S.A., Valent Pharmaceutical, Galderma, Johnson & Johnson, Novartis AG, Moberg Pharma AB, Cardinal Health, Inc., Pfizer Inc., Almirall, S.A., Bayer AG, Viatris Inc., GlaxoSmithKline plc, Cipla Ltd., and Dr. Reddy’s Laboratories Ltd.
Recent Developments in the Market Include
| Attributes | Details |
|---|---|
| Onychomycosis Treatment Market Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Onychomycosis Treatment Market Analysis | US$ million in value |
| Onychomycosis Treatment Market - Key Regions Covered |
|
| Key Countries Covered |
|
| Onychomycosis Treatment Market - Key Segments Covered |
|
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, brand share analysis, competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The onychomycosis treatment market is worth US$ 4,738.3 million in 2023.
The onychomycosis treatment market is predicted to rise at an 8.4% CAGR through 2033.
The onychomycosis treatment market is estimated to be worth US$ 10,608.8 million by 2033.
The drugs segment leads the onychomycosis treatment market with 59.4% shares acquired in 2022.
China holds prominence, with 13.2% of shares captured in 2022.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2023 to 2033
5.3.1. Drugs
5.3.1.1. Oral
5.3.1.2. Topical
5.3.2. Lasers
5.3.2.1. C02 Ablative Lasers
5.3.2.2. Nd: YAG Lasers
5.3.2.3. Dual-wavelength near-infrared Lasers
5.3.3. Photodynamic Therapy
5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Indication
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Disease Indication, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Indication, 2023 to 2033
6.3.1. Distal Subungual Onychomycosis
6.3.2. White Superficial Onychomycosis
6.3.3. Proximal Subungual Onychomycosis
6.3.4. Candidal Onychomycosis
6.3.5. Total Dystrophic Onychomycosis
6.4. Y-o-Y Growth Trend Analysis By Disease Indication, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Disease Indication, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Age Group
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Age Group , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Age Group , 2023 to 2033
7.3.1. 0-18 Years
7.3.2. 18-39 Years
7.3.3. 40-64 Years
7.3.4. 65 Years & Above
7.4. Y-o-Y Growth Trend Analysis By Age Group , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Age Group , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Gender
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By Gender, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Gender, 2023 to 2033
8.3.1. Male
8.3.2. Female
8.4. Y-o-Y Growth Trend Analysis By Gender, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By Gender, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
9.1. Introduction / Key Findings
9.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
9.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
9.3.1. Institutional Sales
9.3.1.1. Hospitals
9.3.1.2. Dermatology Clinics
9.3.2. Retail Sales
9.3.2.1. Retail Pharmacies
9.3.2.2. Drug Stores
9.3.2.3. Mail Order Pharmacies & Online Sales
9.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
9.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
10.1. Introduction
10.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
10.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
10.3.1. North America
10.3.2. Latin America
10.3.3. Western Europe
10.3.4. Eastern Europe
10.3.5. South Asia and Pacific
10.3.6. East Asia
10.3.7. Middle East and Africa
10.4. Market Attractiveness Analysis By Region
11. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. USA.
11.2.1.2. Canada
11.2.2. By Treatment Type
11.2.3. By Disease Indication
11.2.4. By Age Group
11.2.5. By Gender
11.2.6. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment Type
11.3.3. By Disease Indication
11.3.4. By Age Group
11.3.5. By Gender
11.3.6. By Distribution Channel
11.4. Key Takeaways
12. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Brazil
12.2.1.2. Mexico
12.2.1.3. Rest of Latin America
12.2.2. By Treatment Type
12.2.3. By Disease Indication
12.2.4. By Age Group
12.2.5. By Gender
12.2.6. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment Type
12.3.3. By Disease Indication
12.3.4. By Age Group
12.3.5. By Gender
12.3.6. By Distribution Channel
12.4. Key Takeaways
13. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. Germany
13.2.1.2. United Kingdom.
13.2.1.3. France
13.2.1.4. Spain
13.2.1.5. Italy
13.2.1.6. Rest of Western Europe
13.2.2. By Treatment Type
13.2.3. By Disease Indication
13.2.4. By Age Group
13.2.5. By Gender
13.2.6. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Treatment Type
13.3.3. By Disease Indication
13.3.4. By Age Group
13.3.5. By Gender
13.3.6. By Distribution Channel
13.4. Key Takeaways
14. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Poland
14.2.1.2. Russia
14.2.1.3. Czech Republic
14.2.1.4. Romania
14.2.1.5. Rest of Eastern Europe
14.2.2. By Treatment Type
14.2.3. By Disease Indication
14.2.4. By Age Group
14.2.5. By Gender
14.2.6. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Treatment Type
14.3.3. By Disease Indication
14.3.4. By Age Group
14.3.5. By Gender
14.3.6. By Distribution Channel
14.4. Key Takeaways
15. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. India
15.2.1.2. Bangladesh
15.2.1.3. Australia
15.2.1.4. New Zealand
15.2.1.5. Rest of South Asia and Pacific
15.2.2. By Treatment Type
15.2.3. By Disease Indication
15.2.4. By Age Group
15.2.5. By Gender
15.2.6. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Treatment Type
15.3.3. By Disease Indication
15.3.4. By Age Group
15.3.5. By Gender
15.3.6. By Distribution Channel
15.4. Key Takeaways
16. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. China
16.2.1.2. Japan
16.2.1.3. South Korea
16.2.2. By Treatment Type
16.2.3. By Disease Indication
16.2.4. By Age Group
16.2.5. By Gender
16.2.6. By Distribution Channel
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Treatment Type
16.3.3. By Disease Indication
16.3.4. By Age Group
16.3.5. By Gender
16.3.6. By Distribution Channel
16.4. Key Takeaways
17. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
17.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
17.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
17.2.1. By Country
17.2.1.1. GCC Countries
17.2.1.2. South Africa
17.2.1.3. Israel
17.2.1.4. Rest of MEA
17.2.2. By Treatment Type
17.2.3. By Disease Indication
17.2.4. By Age Group
17.2.5. By Gender
17.2.6. By Distribution Channel
17.3. Market Attractiveness Analysis
17.3.1. By Country
17.3.2. By Treatment Type
17.3.3. By Disease Indication
17.3.4. By Age Group
17.3.5. By Gender
17.3.6. By Distribution Channel
17.4. Key Takeaways
18. Key Countries Market Analysis
18.1. USA.
18.1.1. Pricing Analysis
18.1.2. Market Share Analysis, 2022
18.1.2.1. By Treatment Type
18.1.2.2. By Disease Indication
18.1.2.3. By Age Group
18.1.2.4. By Gender
18.1.2.5. By Distribution Channel
18.2. Canada
18.2.1. Pricing Analysis
18.2.2. Market Share Analysis, 2022
18.2.2.1. By Treatment Type
18.2.2.2. By Disease Indication
18.2.2.3. By Age Group
18.2.2.4. By Gender
18.2.2.5. By Distribution Channel
18.3. Brazil
18.3.1. Pricing Analysis
18.3.2. Market Share Analysis, 2022
18.3.2.1. By Treatment Type
18.3.2.2. By Disease Indication
18.3.2.3. By Age Group
18.3.2.4. By Gender
18.3.2.5. By Distribution Channel
18.4. Mexico
18.4.1. Pricing Analysis
18.4.2. Market Share Analysis, 2022
18.4.2.1. By Treatment Type
18.4.2.2. By Disease Indication
18.4.2.3. By Age Group
18.4.2.4. By Gender
18.4.2.5. By Distribution Channel
18.5. Germany
18.5.1. Pricing Analysis
18.5.2. Market Share Analysis, 2022
18.5.2.1. By Treatment Type
18.5.2.2. By Disease Indication
18.5.2.3. By Age Group
18.5.2.4. By Gender
18.5.2.5. By Distribution Channel
18.6. United Kingdom.
18.6.1. Pricing Analysis
18.6.2. Market Share Analysis, 2022
18.6.2.1. By Treatment Type
18.6.2.2. By Disease Indication
18.6.2.3. By Age Group
18.6.2.4. By Gender
18.6.2.5. By Distribution Channel
18.7. France
18.7.1. Pricing Analysis
18.7.2. Market Share Analysis, 2022
18.7.2.1. By Treatment Type
18.7.2.2. By Disease Indication
18.7.2.3. By Age Group
18.7.2.4. By Gender
18.7.2.5. By Distribution Channel
18.8. Spain
18.8.1. Pricing Analysis
18.8.2. Market Share Analysis, 2022
18.8.2.1. By Treatment Type
18.8.2.2. By Disease Indication
18.8.2.3. By Age Group
18.8.2.4. By Gender
18.8.2.5. By Distribution Channel
18.9. Italy
18.9.1. Pricing Analysis
18.9.2. Market Share Analysis, 2022
18.9.2.1. By Treatment Type
18.9.2.2. By Disease Indication
18.9.2.3. By Age Group
18.9.2.4. By Gender
18.9.2.5. By Distribution Channel
18.10. Poland
18.10.1. Pricing Analysis
18.10.2. Market Share Analysis, 2022
18.10.2.1. By Treatment Type
18.10.2.2. By Disease Indication
18.10.2.3. By Age Group
18.10.2.4. By Gender
18.10.2.5. By Distribution Channel
18.11. Russia
18.11.1. Pricing Analysis
18.11.2. Market Share Analysis, 2022
18.11.2.1. By Treatment Type
18.11.2.2. By Disease Indication
18.11.2.3. By Age Group
18.11.2.4. By Gender
18.11.2.5. By Distribution Channel
18.12. Czech Republic
18.12.1. Pricing Analysis
18.12.2. Market Share Analysis, 2022
18.12.2.1. By Treatment Type
18.12.2.2. By Disease Indication
18.12.2.3. By Age Group
18.12.2.4. By Gender
18.12.2.5. By Distribution Channel
18.13. Romania
18.13.1. Pricing Analysis
18.13.2. Market Share Analysis, 2022
18.13.2.1. By Treatment Type
18.13.2.2. By Disease Indication
18.13.2.3. By Age Group
18.13.2.4. By Gender
18.13.2.5. By Distribution Channel
18.14. India
18.14.1. Pricing Analysis
18.14.2. Market Share Analysis, 2022
18.14.2.1. By Treatment Type
18.14.2.2. By Disease Indication
18.14.2.3. By Age Group
18.14.2.4. By Gender
18.14.2.5. By Distribution Channel
18.15. Bangladesh
18.15.1. Pricing Analysis
18.15.2. Market Share Analysis, 2022
18.15.2.1. By Treatment Type
18.15.2.2. By Disease Indication
18.15.2.3. By Age Group
18.15.2.4. By Gender
18.15.2.5. By Distribution Channel
18.16. Australia
18.16.1. Pricing Analysis
18.16.2. Market Share Analysis, 2022
18.16.2.1. By Treatment Type
18.16.2.2. By Disease Indication
18.16.2.3. By Age Group
18.16.2.4. By Gender
18.16.2.5. By Distribution Channel
18.17. New Zealand
18.17.1. Pricing Analysis
18.17.2. Market Share Analysis, 2022
18.17.2.1. By Treatment Type
18.17.2.2. By Disease Indication
18.17.2.3. By Age Group
18.17.2.4. By Gender
18.17.2.5. By Distribution Channel
18.18. China
18.18.1. Pricing Analysis
18.18.2. Market Share Analysis, 2022
18.18.2.1. By Treatment Type
18.18.2.2. By Disease Indication
18.18.2.3. By Age Group
18.18.2.4. By Gender
18.18.2.5. By Distribution Channel
18.19. Japan
18.19.1. Pricing Analysis
18.19.2. Market Share Analysis, 2022
18.19.2.1. By Treatment Type
18.19.2.2. By Disease Indication
18.19.2.3. By Age Group
18.19.2.4. By Gender
18.19.2.5. By Distribution Channel
18.20. South Korea
18.20.1. Pricing Analysis
18.20.2. Market Share Analysis, 2022
18.20.2.1. By Treatment Type
18.20.2.2. By Disease Indication
18.20.2.3. By Age Group
18.20.2.4. By Gender
18.20.2.5. By Distribution Channel
18.21. GCC Countries
18.21.1. Pricing Analysis
18.21.2. Market Share Analysis, 2022
18.21.2.1. By Treatment Type
18.21.2.2. By Disease Indication
18.21.2.3. By Age Group
18.21.2.4. By Gender
18.21.2.5. By Distribution Channel
18.22. South Africa
18.22.1. Pricing Analysis
18.22.2. Market Share Analysis, 2022
18.22.2.1. By Treatment Type
18.22.2.2. By Disease Indication
18.22.2.3. By Age Group
18.22.2.4. By Gender
18.22.2.5. By Distribution Channel
18.23. Israel
18.23.1. Pricing Analysis
18.23.2. Market Share Analysis, 2022
18.23.2.1. By Treatment Type
18.23.2.2. By Disease Indication
18.23.2.3. By Age Group
18.23.2.4. By Gender
18.23.2.5. By Distribution Channel
19. Market Structure Analysis
19.1. Competition Dashboard
19.2. Competition Benchmarking
19.3. Market Share Analysis of Top Players
19.3.1. By Regional
19.3.2. By Treatment Type
19.3.3. By Disease Indication
19.3.4. By Age Group
19.3.5. By Gender
19.3.6. By Distribution Channel
20. Competition Analysis
20.1. Competition Deep Dive
20.1.1. Teva Pharmaceutical Industries Ltd.
20.1.1.1. Overview
20.1.1.2. Product Portfolio
20.1.1.3. Profitability by Market Segments
20.1.1.4. Sales Footprint
20.1.1.5. Strategy Overview
20.1.1.5.1. Marketing Strategy
20.1.2. Sanofi S.A.
20.1.2.1. Overview
20.1.2.2. Product Portfolio
20.1.2.3. Profitability by Market Segments
20.1.2.4. Sales Footprint
20.1.2.5. Strategy Overview
20.1.2.5.1. Marketing Strategy
20.1.3. Medimetriks Pharmaceuticals, Inc.
20.1.3.1. Overview
20.1.3.2. Product Portfolio
20.1.3.3. Profitability by Market Segments
20.1.3.4. Sales Footprint
20.1.3.5. Strategy Overview
20.1.3.5.1. Marketing Strategy
20.1.4. Galderma
20.1.4.1. Overview
20.1.4.2. Product Portfolio
20.1.4.3. Profitability by Market Segments
20.1.4.4. Sales Footprint
20.1.4.5. Strategy Overview
20.1.4.5.1. Marketing Strategy
20.1.5. Johnson & Johnson
20.1.5.1. Overview
20.1.5.2. Product Portfolio
20.1.5.3. Profitability by Market Segments
20.1.5.4. Sales Footprint
20.1.5.5. Strategy Overview
20.1.5.5.1. Marketing Strategy
20.1.6. Novartis AG
20.1.6.1. Overview
20.1.6.2. Product Portfolio
20.1.6.3. Profitability by Market Segments
20.1.6.4. Sales Footprint
20.1.6.5. Strategy Overview
20.1.6.5.1. Marketing Strategy
20.1.7. Moberg Pharma AB
20.1.7.1. Overview
20.1.7.2. Product Portfolio
20.1.7.3. Profitability by Market Segments
20.1.7.4. Sales Footprint
20.1.7.5. Strategy Overview
20.1.7.5.1. Marketing Strategy
20.1.8. Cardinal Health, Inc.
20.1.8.1. Overview
20.1.8.2. Product Portfolio
20.1.8.3. Profitability by Market Segments
20.1.8.4. Sales Footprint
20.1.8.5. Strategy Overview
20.1.8.5.1. Marketing Strategy
20.1.9. Pfizer Inc.
20.1.9.1. Overview
20.1.9.2. Product Portfolio
20.1.9.3. Profitability by Market Segments
20.1.9.4. Sales Footprint
20.1.9.5. Strategy Overview
20.1.9.5.1. Marketing Strategy
20.1.10. Almirall, S.A.
20.1.10.1. Overview
20.1.10.2. Product Portfolio
20.1.10.3. Profitability by Market Segments
20.1.10.4. Sales Footprint
20.1.10.5. Strategy Overview
20.1.10.5.1. Marketing Strategy
20.1.11. Bayer AG
20.1.11.1. Overview
20.1.11.2. Product Portfolio
20.1.11.3. Profitability by Market Segments
20.1.11.4. Sales Footprint
20.1.11.5. Strategy Overview
20.1.11.5.1. Marketing Strategy
20.1.12. Viatris Inc.
20.1.12.1. Overview
20.1.12.2. Product Portfolio
20.1.12.3. Profitability by Market Segments
20.1.12.4. Sales Footprint
20.1.12.5. Strategy Overview
20.1.12.5.1. Marketing Strategy
20.1.13. GlaxoSmithKline plc
20.1.13.1. Overview
20.1.13.2. Product Portfolio
20.1.13.3. Profitability by Market Segments
20.1.13.4. Sales Footprint
20.1.13.5. Strategy Overview
20.1.13.5.1. Marketing Strategy
20.1.14. Cipla Ltd.
20.1.14.1. Overview
20.1.14.2. Product Portfolio
20.1.14.3. Profitability by Market Segments
20.1.14.4. Sales Footprint
20.1.14.5. Strategy Overview
20.1.14.5.1. Marketing Strategy
20.1.15. Dr. Reddy’s Laboratories Ltd
20.1.15.1. Overview
20.1.15.2. Product Portfolio
20.1.15.3. Profitability by Market Segments
20.1.15.4. Sales Footprint
20.1.15.5. Strategy Overview
20.1.15.5.1. Marketing Strategy
21. Assumptions & Acronyms Used
22. Research Methodology
Explore Healthcare Insights
View Reports
Onychomycosis Treatment Market
